What is Sana Biotechnology Financial Strength?
Sana Biotechnology has the Financial Strength Rank of 6.
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:
1. The debt burden that the company has as measured by its
Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3.
Altman Z-Score.
GuruFocus does not calculate Sana Biotechnology's interest coverage with the available data.
As of today, Sana Biotechnology's Altman Z-Score is 0.00.
Competitive Comparison of Sana Biotechnology's Financial Strength
For the Biotechnology subindustry, Sana Biotechnology's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sana Biotechnology's Financial Strength Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sana Biotechnology's Financial Strength distribution charts can be found below:
* The bar in red indicates where Sana Biotechnology's Financial Strength falls into.
Sana Biotechnology Financial Strength Calculation
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
Sana Biotechnology's Interest Expense for the
months ended in Mar. 2024 was $0.00 Mil. Its Operating Income for the
months ended in Mar. 2024 was $-110.72 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $92.92 Mil.
Sana Biotechnology's Interest Coverage for the quarter that ended in Mar. 2024 is
| GuruFocus does not calculate Sana Biotechnology's interest coverage with the available data. |
The higher the ratio, the stronger the company's financial strength is.
Good Sign:
Ben Graham prefers companies' interest coverage to be at least 5. Sana Biotechnology Inc has enough cash to cover all of its debt. Its financial situation is stable.
2. Debt to revenue ratio. The lower, the better.
Sana Biotechnology's Debt to Revenue Ratio for the quarter that ended in Mar. 2024 is
3. Altman Z-Score.
Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
The zones of discrimination were as such:
When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.
Sana Biotechnology has a Z-score of 0.00, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sana Biotechnology (Sana Biotechnology) Business Description
Traded in Other Exchanges
N/A
Address
188 East Blaine Street, Suite 400, Seattle, WA, USA, 98102
Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. Its operations include identifying and developing potential product candidates, executing preclinical studies, establishing manufacturing capabilities, acquiring technology, organizing and staffing the Company, business planning, establishing the company's intellectual property portfolio, raising capital, and providing general and administrative support for these operations.
Executives
| Christian Hordo |
officer: SVP, Chief Business Officer |
C/O SANA BIOTECHNOLOGY, INC., 188 EAST BLAINE STREET, SUITE 400, SEATTLE WA 98102 |
| Flagship Ventures Fund V, L.p. |
10 percent owner |
ONE MEMORIAL DRIVE, 7TH FLOOR, CAMBRIDGE MA 02142 |
| Douglas E Williams |
officer: EVP & President, R&D |
C/O AMGEN INC, ONE AMGEN CENTER DR, THOUSAND OAKS CA 91320-1799 |
| Bernard J Cassidy |
officer: EVP & General Counsel |
C/O TUMBLEWEED COMMUNICATIONS CORP, 700 SAGINAW DRIVE, REDWOOD CITY CA 94063 |
| Patrick Y Yang |
director |
C/O GENENTECH INC, 1 DNA WAY,MS 49,ATTN:K.STRAND OR J.BERRY, SOUTH SAN FRANCISCO CA 94080-4990 |
| James J. Macdonald |
officer: See Remarks |
C/O SANA BIOTECHNOLOGY, INC., 188 EAST BLAINE STREET, SUITE 400, SEATTLE WA 98102 |
| Sunil Agarwal |
officer: See Remarks |
60 LEVERONI COURT, NOVATO CA 94949 |
| Arch Venture Partners Ix, L.p. |
10 percent owner |
8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631 |
| Flagship Venturelabs V Manager Llc |
10 percent owner |
55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE MA 02142 |
| Flagship Ventures Fund V General Partner Llc |
10 percent owner |
55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE MA 02142 |
| Flagship V Venturelabs Rx Fund, L.p. |
10 percent owner |
55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE MA 02142 |
| Flagship Venturelabs V Llc |
10 percent owner |
55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE MA 02142 |
| Arch Venture Fund Ix, L.p. |
10 percent owner |
8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631 |
| Arch Venture Fund Ix Overage, L.p. |
10 percent owner |
8725 W. HIGGINS ROAD, SUITE 290, CHICAGO IL 60631 |
| Arch Venture Partners Ix Overage, L.p. |
10 percent owner |
8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631 |
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
SANA has been successfully added to your